XML 59 R42.htm IDEA: XBRL DOCUMENT v3.20.2
Intangible Assets (Details Narrative) - USD ($)
3 Months Ended 6 Months Ended 12 Months Ended
Dec. 31, 2016
Jun. 30, 2020
Mar. 31, 2020
Jun. 30, 2019
Jun. 30, 2020
Jun. 30, 2019
Dec. 31, 2019
Dec. 31, 2018
Finite-lived intangible assets, net   $ 227,318     $ 227,318   $ 340,976  
2018 Aspire Purchase Agreements [Member]                
Finite-lived intangible assets, net             340,976  
Finite-lived intangible assets, accumulated amortization             1,250,238  
IPR&D Drug Technology Platforms [Member]                
Asset impairment charges, total              
IPR&D Drug Technology Platforms [Member] | Ovarian Cancer [Member]                
Asset impairment charges, total $ 13,300,000            
EGEN Inc [Member]                
Goodwill, acquisition         2,000,000      
EGEN Inc [Member] | Purchase Agreement [Member]                
Finite-lived intangible assets acquired         $ 1,600,000      
Finite-lived intangible asset, useful life         7 years      
Amortization expense   56,829   $ 56,829 $ 113,658 $ 113,658    
Finite-lived intangible assets, net   227,318     227,318      
Finite-lived intangible assets, accumulated amortization   $ 1,363,896     1,363,896      
EGEN Inc [Member] | Glioblastoma Multiforme Brain Cancer [Member]                
Asset impairment charges, total     $ 2,400,000       $ 7,000,000 $ 9,400,000
EGEN Inc [Member] | RNA Delivery System [Member]                
Asset impairment charges, total         1,500,000      
EGEN Inc [Member] | IPR&D Drug Technology Platforms [Member]                
Indefinite lived intangible assets         $ 24,200,000